424 related articles for article (PubMed ID: 22252613)
21. Total body irradiation compared with BEAM: Long-term outcomes of peripheral blood autologous stem cell transplantation for non-Hodgkin's lymphoma.
Liu HW; Seftel MD; Rubinger M; Szwajcer D; Demers A; Nugent Z; Schroeder G; Butler JB; Cooke A
Int J Radiat Oncol Biol Phys; 2010 Oct; 78(2):513-20. PubMed ID: 20137862
[TBL] [Abstract][Full Text] [Related]
22. Etoposide pharmacokinetics impact the outcomes of lymphoma patients treated with BEAM regimen and ASCT: a multicenter study of the LYmphoma Study Association (LYSA).
You B; Salles G; Bachy E; Casasnovas O; Tilly H; Ribrag V; Sebban C; Hénin E; Guitton J; Tod M; Freyer G
Cancer Chemother Pharmacol; 2015 Nov; 76(5):939-48. PubMed ID: 26391155
[TBL] [Abstract][Full Text] [Related]
23. Autologous stem cell transplantation after conditioning with yttrium-90 ibritumomab tiuxetan plus BEAM in refractory non-Hodgkin diffuse large B-cell lymphoma: results of a prospective, multicenter, phase II clinical trial.
Briones J; Novelli S; García-Marco JA; Tomás JF; Bernal T; Grande C; Canales MA; Torres A; Moraleda JM; Panizo C; Jarque I; Palmero F; Hernández M; González-Barca E; López D; Caballero D;
Haematologica; 2014 Mar; 99(3):505-10. PubMed ID: 24162789
[TBL] [Abstract][Full Text] [Related]
24. Yttrium-90 ibritumomab tiuxetan doses calculated to deliver up to 15 Gy to critical organs may be safely combined with high-dose BEAM and autologous transplantation in relapsed or refractory B-cell non-Hodgkin's lymphoma.
Winter JN; Inwards DJ; Spies S; Wiseman G; Patton D; Erwin W; Rademaker AW; Weitner BB; Williams SF; Tallman MS; Micallef I; Mehta J; Singhal S; Evens AM; Zimmer M; Molina A; White CA; Gordon LI
J Clin Oncol; 2009 Apr; 27(10):1653-9. PubMed ID: 19255322
[TBL] [Abstract][Full Text] [Related]
25. Yttrium-90-ibritumomab tiuxetan in combination with intravenous busulfan, cyclophosphamide, and etoposide followed by autologous stem cell transplantation in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma.
Kang BW; Kim WS; Kim C; Jang G; Lee SS; Choi YH; Lee DH; Kim SW; Kim S; Ryu JS; Huh J; Lee JS; Suh C
Invest New Drugs; 2010 Aug; 28(4):516-22. PubMed ID: 19547918
[TBL] [Abstract][Full Text] [Related]
26. Nordic MCL3 study: 90Y-ibritumomab-tiuxetan added to BEAM/C in non-CR patients before transplant in mantle cell lymphoma.
Kolstad A; Laurell A; Jerkeman M; Grønbæk K; Elonen E; Räty R; Pedersen LB; Loft A; Bogsrud TV; Kimby E; Hansen PB; Fagerli UM; Nilsson-Ehle H; Lauritzsen GF; Lehmann AK; Sundstrom C; Karjalainen-Lindsberg ML; Ralfkiaer E; Ehinger M; Delabie J; Bentzen H; Schildt J; Kostova-Aherdan K; Frederiksen H; Brown Pde N; Geisler CH;
Blood; 2014 May; 123(19):2953-9. PubMed ID: 24652994
[TBL] [Abstract][Full Text] [Related]
27. A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma.
Nademanee A; Forman S; Molina A; Fung H; Smith D; Dagis A; Kwok C; Yamauchi D; Anderson AL; Falk P; Krishnan A; Kirschbaum M; Kogut N; Nakamura R; O'donnell M; Parker P; Popplewell L; Pullarkat V; Rodriguez R; Sahebi F; Smith E; Snyder D; Stein A; Spielberger R; Zain J; White C; Raubitschek A
Blood; 2005 Oct; 106(8):2896-902. PubMed ID: 16002426
[TBL] [Abstract][Full Text] [Related]
28. Pretransplantation positron emission tomography scan is the main predictor of autologous stem cell transplantation outcome in aggressive B-cell non-Hodgkin lymphoma.
Derenzini E; Musuraca G; Fanti S; Stefoni V; Tani M; Alinari L; Venturini F; Gandolfi L; Baccarani M; Zinzani PL
Cancer; 2008 Nov; 113(9):2496-503. PubMed ID: 18833583
[TBL] [Abstract][Full Text] [Related]
29. DexaBEAM versus ICE salvage regimen prior to autologous transplantation for relapsed or refractory aggressive peripheral T cell lymphoma: a retrospective evaluation of parallel patient cohorts of one center.
Mikesch JH; Kuhlmann M; Demant A; Krug U; Thoennissen GB; Schmidt E; Kessler T; Schliemann C; Pohlen M; Mohr M; Evers G; Köhler G; Wessling J; Mesters R; Müller-Tidow C; Berdel WE; Thoennissen NH
Ann Hematol; 2013 Aug; 92(8):1041-8. PubMed ID: 23532626
[TBL] [Abstract][Full Text] [Related]
30. Autologous bone marrow transplantation for patients with relapsed or refractory diffuse aggressive non-Hodgkin's lymphoma: value of augmented preparative regimens--a Southwest Oncology Group trial.
Stiff PJ; Dahlberg S; Forman SJ; McCall AR; Horning SJ; Nademanee AP; Blume KG; LeBlanc M; Fisher RI
J Clin Oncol; 1998 Jan; 16(1):48-55. PubMed ID: 9440722
[TBL] [Abstract][Full Text] [Related]
31. A retrospective, matched paired analysis comparing bendamustine containing BeEAM versus BEAM conditioning regimen: results from a single center experience.
Saleh K; Danu A; Koscielny S; Legoupil C; Pilorge S; Castilla-Llorente C; Ghez D; Lazarovici J; Michot JM; Khalife-Saleh N; Lapierre V; Alenxandrova K; Arfi-Rouche J; Bourhis JH; Ribrag V
Leuk Lymphoma; 2018 Nov; 59(11):2580-2587. PubMed ID: 29164977
[TBL] [Abstract][Full Text] [Related]
32. Phase II trial of 131-Iodine tositumomab with high-dose chemotherapy and autologous stem cell transplantation for relapsed diffuse large B cell lymphoma.
Vose JM; Bierman PJ; Loberiza FR; Enke C; Hankins J; Bociek RG; Chan WC; Weisenburger DD; Armitage JO
Biol Blood Marrow Transplant; 2013 Jan; 19(1):123-8. PubMed ID: 22940055
[TBL] [Abstract][Full Text] [Related]
33. Dose-escalated CHOP and tailored intensification with IFE according to early response and followed by BEAM/autologous stem-cell transplantation in poor-risk aggressive B-cell lymphoma: a prospective study from the GEL-TAMO Study Group.
Arranz R; Conde E; Grande C; Mateos MV; Gandarillas M; Albo C; Lahuerta JJ; Fernández-Rañada JM; Hernández MT; Alonso N; García Vela JA; Garzón S; Rodríguez J; Caballero D;
Eur J Haematol; 2008 Mar; 80(3):227-35. PubMed ID: 18088400
[TBL] [Abstract][Full Text] [Related]
34. BEAM or BuCyE high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma patients: a single center comparative analysis of efficacy and toxicity.
Kim JE; Lee DH; Yoo C; Kim S; Kim SW; Lee JS; Park CJ; Huh J; Suh C
Leuk Res; 2011 Feb; 35(2):183-7. PubMed ID: 20684990
[TBL] [Abstract][Full Text] [Related]
35. Dexamethasone, carmustine, etoposide, cytarabine, and melphalan (dexa-BEAM) followed by high-dose chemotherapy and stem cell rescue--a highly effective regimen for patients with refractory or relapsed indolent lymphoma.
Josting A; Reiser M; Wickramanayake PD; Rueffer U; Draube A; Söhngen D; Tesch H; Wolf J; Diehl V; Engert A
Leuk Lymphoma; 2000 Mar; 37(1-2):115-23. PubMed ID: 10721775
[TBL] [Abstract][Full Text] [Related]
36. Phase II Study of Yttrium-90-Ibritumomab Tiuxetan as Part of Reduced-Intensity Conditioning (with Melphalan, Fludarabine ± Thiotepa) for Allogeneic Transplantation in Relapsed or Refractory Aggressive B Cell Lymphoma: A GELTAMO Trial.
Cabrero M; Martin A; Briones J; Gayoso J; Jarque I; López J; Grande C; Heras I; Arranz R; Bernal T; Perez-Lopez E; López-Godino O; Conde E; Caballero D
Biol Blood Marrow Transplant; 2017 Jan; 23(1):53-59. PubMed ID: 27771496
[TBL] [Abstract][Full Text] [Related]
37. Autologous stem cell transplantation for follicular lymphoma is of most benefit early in the disease course and can result in durable remissions, irrespective of prior rituximab exposure.
Kothari J; Peggs KS; Bird A; Thomson KJ; Morris E; Virchis AE; Lambert J; Goldstone AH; Linch DC; Ardeshna KM
Br J Haematol; 2014 May; 165(3):334-40. PubMed ID: 24438080
[TBL] [Abstract][Full Text] [Related]
38. Carmustine, etoposide, cytarabine, and melphalan (BEAM)-campath allogeneic stem cell transplantation for aggressive non-hodgkin lymphoma: an analysis of outcomes from the British Society of Blood and Marrow Transplantation.
Truelove E; Fox C; Robinson S; Pearce R; Perry J; Kirkland K; McQuaker G; Pagliuca A; Johnson P; Russell N; Cook G;
Biol Blood Marrow Transplant; 2015 Mar; 21(3):483-8. PubMed ID: 25490180
[TBL] [Abstract][Full Text] [Related]
39. High dose chemotherapy and autologous stem cell transplantation for poor risk and recurrent non-Hodgkin's lymphoma: a single-center experience of 50 patients.
Shim BY; Lee MA; Byun JH; Roh SY; Song CW; Park JN; Lee JW; Min WS; Hong YS; Kim CC
Korean J Intern Med; 2004 Jun; 19(2):114-20. PubMed ID: 15366643
[TBL] [Abstract][Full Text] [Related]
40. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]